Susquehanna International Group, LLP Aurinia Pharmaceuticals Inc. Transaction History

Susquehanna International Group, LLP

$568 Billion
Q1 2024

A detailed history of Susquehanna International Group, LLP transactions in Aurinia Pharmaceuticals Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 337,757 shares of AUPH stock, worth $1.93 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

337,757

Previous 1,032,604 67.29%

Holding current value

$1.93 Million

Previous $9.28 Million 81.77%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 07, 2024	SELL	$4.93 - $9.31 $3.43 Million - $6.47 Million	-694,847 Reduced 67.29%	337,757 $1.69 Million
Q4 2023 Feb 14, 2024	BUY	$7.13 - $9.49 $3.03 Million - $4.03 Million	424,708 Added 69.87%	1,032,604 $9.28 Million
Q3 2023 Nov 14, 2023	SELL	$7.77 - $12.27 $1.53 Million - $2.41 Million	-196,590 Reduced 24.44%	607,896 $4.72 Million
Q2 2023 Aug 11, 2023	SELL	$8.96 - $11.69 $2.27 Million - $2.96 Million	-253,151 Reduced 23.94%	804,486 $7.79 Million
Q1 2023 May 16, 2023	BUY	$5.94 - $11.27 $2.23 Million - $4.24 Million	375,975 Added 55.16%	1,057,637 $11.6 Million

Q4 2022 Feb 14, 2023	SELL	$4.11 - $8.14 $389,295 - $771,012	-94,719 Reduced 12.2%	681,662 $2.94 Million
Q3 2022 Nov 14, 2022	SELL	$6.66 - $12.39 $6.26 Million - $11.7 Million	-940,586 Reduced 54.78%	776,381 $5.84 Million
Q2 2022 Aug 15, 2022	SELL	$8.95 - $12.8 $1.84 Million - $2.64 Million	-206,038 Reduced 10.71%	1,716,967 $17.3 Million
Q1 2022 May 16, 2022	SELL	$10.05 - $22.48 $14.8 Million - $33 Million	-1,469,001 Reduced 43.31%	1,923,005 $23.8 Million
Q4 2021 Feb 14, 2022	SELL	$17.78 - $33.08 $7.66 Million - $14.3 Million	-430,821 Reduced 11.27%	3,392,006 $77.6 Million
Q3 2021 Nov 15, 2021	BUY	$10.93 - $23.55 $15.4 Million - $33.1 Million	1,406,345 Added 58.2%	3,822,827 $84.6 Million
Q2 2021 Aug 11, 2021	BUY	$10.0 - $14.52 $10.6 Million - $15.4 Million	1,062,348 Added 78.45%	2,416,482 $31.3 Million
Q1 2021 May 17, 2021	SELL	$12.3 - $18.73 $9.01 Million - $13.7 Million	-732,263 Reduced 35.1%	1,354,134 $17.6 Million
Q4 2020 Feb 16, 2021	BUY	$12.94 - $16.05 $8.71 Million - $10.8 Million	673,219 Added 47.64%	2,086,397 $28.9 Million
Q3 2020 Nov 16, 2020	BUY	$13.19 - $16.66 $4.19 Million - $5.29 Million	317,579 Added 28.99%	1,413,178 $20.8 Million
Q2 2020 Aug 14, 2020	SELL	$14.12 - $18.33 $40,270 - $52,277	-2,852 Reduced 0.26%	1,095,599 $17.8 Million
Q1 2020 May 15, 2020	BUY	$11.34 - $21.46 $2.68 Million - $5.08 Million	236,581 Added 27.45%	1,098,451 $15.9 Million
Q4 2019 Feb 14, 2020	BUY	$3.88 - $21.42 $851,015 - $4.7 Million	219,334 Added 34.14%	861,870 $17.5 Million
Q3 2019 Nov 14, 2019	BUY	$5.34 - $6.59 $802,233 - $990,022	150,231 Added 30.52%	642,536 $3.43 Million
Q2 2019 Aug 16, 2019	BUY	$6.05 - $6.75 $11,277 - $12,582	1,864 Added 0.38%	492,305 $3.24 Million
Q2 2019 Aug 14, 2019	SELL	$6.05 - $6.75 $476,262 - $531,366	-78,721 Reduced 13.83%	490,441 $3.23 Million
Q1 2019 May 15, 2019	BUY	$6.06 - $7.64 $1.8 Million - $2.27 Million	297,328 Added 109.38%	569,162 $3.7 Million
Q4 2018 Feb 14, 2019	BUY	$5.08 - $6.83 $721,639 - $970,235	142,055 Added 109.46%	271,834 $1.85 Million
Q3 2018 Nov 14, 2018	SELL	$5.27 - $6.64 $425,510 - $536,126	-80,742 Reduced 38.35%	129,779 $862,000
Q2 2018 Aug 14, 2018	BUY	$5.06 - $6.36 $584,394 - $734,535	115,493 Added 121.54%	210,521 $1.19 Million
Q1 2018 May 15, 2018	SELL	$4.85 - $5.99 $219,860 - $271,538	-45,332 Reduced 32.3%	95,028 $493,000
Q4 2017 Feb 14, 2018	SELL	$4.53 - $7.09 $757,941 - $1.19 Million	-167,316 Reduced 54.38%	140,360 $636,000
Q3 2017 Nov 14, 2017	BUY	$5.71 - $6.9 $1.76 Million - $2.12 Million	307,676	307,676 $1.93 Million

Others Institutions Holding AUPH

# of Institutions

205

Shares Held

55.6M

Call Options Held

838K

Put Options Held

1.18M

View Full List

About Aurinia Pharmaceuticals Inc.

Ticker AUPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,892,000
Market Cap $810M
Description
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...

More about AUPH

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Account

Susquehanna International Group, LLP Aurinia Pharmaceuticals Inc. Transaction History